Soleus Capital Management L.P. Purchases 1,319,700 Shares of Celcuity Inc. (NASDAQ:CELC)

Soleus Capital Management L.P. grew its holdings in shares of Celcuity Inc. (NASDAQ:CELC - Free Report) by 106.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,565,087 shares of the company's stock after acquiring an additional 1,319,700 shares during the period. Celcuity accounts for approximately 2.1% of Soleus Capital Management L.P.'s investment portfolio, making the stock its 14th biggest holding. Soleus Capital Management L.P. owned approximately 6.91% of Celcuity worth $33,577,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Summit Investment Advisors Inc. boosted its position in shares of Celcuity by 49.5% during the 4th quarter. Summit Investment Advisors Inc. now owns 3,421 shares of the company's stock valued at $45,000 after purchasing an additional 1,132 shares in the last quarter. Corebridge Financial Inc. grew its position in shares of Celcuity by 12.9% during the 4th quarter. Corebridge Financial Inc. now owns 16,256 shares of the company's stock worth $213,000 after buying an additional 1,858 shares during the period. JPMorgan Chase & Co. increased its stake in shares of Celcuity by 22.3% in the 4th quarter. JPMorgan Chase & Co. now owns 14,683 shares of the company's stock valued at $192,000 after acquiring an additional 2,676 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Celcuity by 16.2% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,725 shares of the company's stock valued at $258,000 after acquiring an additional 2,756 shares in the last quarter. Finally, Barclays PLC lifted its position in shares of Celcuity by 6.7% during the 4th quarter. Barclays PLC now owns 57,199 shares of the company's stock valued at $749,000 after acquiring an additional 3,594 shares during the period. 63.33% of the stock is owned by institutional investors.

Celcuity Stock Up 0.9%

Celcuity stock opened at $10.61 on Monday. The firm has a market capitalization of $401.47 million, a price-to-earnings ratio of -4.07 and a beta of 0.56. The firm's fifty day moving average price is $10.15 and its two-hundred day moving average price is $11.64. Celcuity Inc. has a 1-year low of $7.58 and a 1-year high of $19.77. The company has a current ratio of 10.35, a quick ratio of 10.36 and a debt-to-equity ratio of 0.65.

Celcuity (NASDAQ:CELC - Get Free Report) last posted its earnings results on Wednesday, May 14th. The company reported ($0.86) earnings per share for the quarter, topping analysts' consensus estimates of ($0.95) by $0.09. On average, equities research analysts predict that Celcuity Inc. will post -2.62 earnings per share for the current fiscal year.

Analyst Ratings Changes

CELC has been the topic of a number of research analyst reports. HC Wainwright reissued a "buy" rating and set a $27.00 price objective on shares of Celcuity in a research report on Tuesday, April 1st. Needham & Company LLC reiterated a "buy" rating and issued a $29.00 price target on shares of Celcuity in a report on Thursday. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $30.80.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.